[1]
L. K. Aloufi, R. K. Almaysari, A. T. Aljehani, A. D. Mohammed D., and Z. M. Alnefaie, “Pharmacological, behavioral, and sociocultural dimensions of GLP-1 and dual incretin therapies in Saudi Arabia: clinical evidence, misuse patterns, and policy priorities”, Int J Basic Clin Pharmacol, vol. 15, no. 1, pp. 158–165, Dec. 2025.